Bernard Escudier, MD, is the former chair of the genitourinary group of the Institut Gustave Roussy in Villejuif, France. Dr. Escudier’s research focuses on renal cell carcinoma, immunotherapy and on development of new therapeutic strategies.
Dr. Escudier received his medical degree from the University of Paris, Paris, France, and initially trained as a cardiologist and then an intensivist. He became the head of the first immunotherapy unit in Gustave Roussy in 1992, and then moved to the Medical Oncology Department.
He has authored more than 400 publications in peer-reviewed journals and is a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the European Society for Medical Oncology.
He is also a member of the board of the Kidney Cancer Association and president of ARTuR (the French association on renal tumours).
Since 1992, Dr. Escudier has been head of the French Group of Immunotherapy, which conducts large multicentre phase 2/3 studies in renal cancer; he is also a principal investigator for many phase 1 to 2 clinical trials in renal cancer.
Dr. Escudier is a member of the ESMO Faculty and was coordinator of Genitourinary Cancer ESMO Faculty Group, 2012-2016. He has also been a member of the Editorial Board of Annals of Oncology, 2012-2014; and of the ESMO Educational Committee, 2012-2016. Since 2016, Dr. Escudier has been a member of the ESMO Open Editorial Board.
ESMO 2017 Congress
"Everyone interested in GU tumours should attend the Genitourinary Tumours (non-prostate) track at ESMO 2017, which will provide the best up-to-date information on non-prostate GU malignancies."
Bernard Escudier was the Genitourinary Tumours (non-prostate) Track Chair of the ESMO 2017 Congress, which took place in Madrid, Spain (8-12 September 2017).